Stock Analiz

Cytek Biosciences, Inc. CTKB

Biotechnology: Laboratory Analytical Instruments · IPO 2021 · data as of November 13, 2026

$5.84Market cap $764M
Open the interactive analysis →

Cytek Biosciences, Inc. (CTKB) is a industrial company listed in the US with a market value of about $764M. In the twelve months to September 30, 2026 it had revenue of $208M and net income of -$81M, a net margin of -39.1%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.

About Cytek Biosciences

Cytek Biosciences is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2021. Revenue went from $93M in 2020 to $201M in 2025, growth of about 16.8% a year. It was profitable in 3 of the last 6 years in our data. Its share count fell by 8% over three years (buybacks). It spends 18% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.7
P/B2.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1.8%
Shareholder yield2.0%
Intrinsic value vs. price−84%

Growth and quality

Revenue growth (1 yr)0.5%
Revenue growth (5 yrs, per year)16.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-7.7%
ROIC (5-yr avg.)-3.5%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$208M$201M$200M$193M$164M$128M$93M
Net income-$81M-$67M-$6M-$12M$2M$3M$19M
Free cash flow-$13M-$9M$22M$633000-$22M$266000$14M
EPS (diluted)$-0.63$-0.52$-0.05$-0.09$0.02$0.00$0.10
Net margin-39.1%-33.0%-3.0%-6.3%1.5%2.4%20.9%
ROIC—-8.9%-4.0%-5.3%-0.3%1.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $6.50, 11% above the current price; targets range from $5.00 to $7.50; the consensus rating is “Buy”; expected EPS is $-0.29 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Cytek Biosciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Cytek Biosciences pay a dividend?

Not currently.

Is Cytek Biosciences a good stock to buy?

We do not give buy or sell advice. Cytek Biosciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.